Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies

ABSTRACT The commercial success of bispecific antibodies generally has been hindered by the complexities associated with generating appropriate molecules for both research scale and large scale manufacturing purposes. Bispecific IgG (BsIgG) based on two antibodies that use an identical common light chain can be combined with a minimal set of Fc mutations to drive heavy chain heterodimerization in order to address these challenges. However, the facile generation of common light chain antibodies with properties similar to traditional monoclonal antibodies has not been demonstrated and they have only been used sparingly. Here, we describe the design of a synthetic human antibody library based on common light chains to generate antibodies with biochemical and biophysical properties that are indistinguishable to traditional therapeutic monoclonal antibodies. We used this library to generate diverse panels of well-behaved, high affinity antibodies toward a variety of epitopes across multiple antigens, including mouse 4-1BB, a therapeutically important T cell costimulatory receptor. Over 200 BsIgG toward 4-1BB were generated using an automated purification method we developed that enables milligram-scale production of BsIgG. This approach allowed us to identify antibodies with a wide range of agonistic activity that are being used to further investigate the therapeutic potential of antibodies targeting one or more epitopes of 4-1BB.

[1]  W. Es VH shuffling can be used to convert an Fv fragment of anti-hen egg lysozyme specificity to one that recognizes a T cell receptor Vα , 1995 .

[2]  Meric A. Ovacik,et al.  Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells , 2016, mAbs.

[3]  J. Xu,et al.  Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. , 2000, Immunity.

[4]  Andrew Leaver-Fay,et al.  Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface , 2014, Nature Biotechnology.

[5]  Ulrik B. Nielsen,et al.  Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.

[6]  Christilyn P. Graff,et al.  A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity , 2011, mAbs.

[7]  Irving L. Weissman,et al.  Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands , 2015, Cell.

[8]  Tsukasa Suzuki,et al.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.

[9]  D. Cox,et al.  Synthetic antibodies designed on natural sequence landscapes. , 2011, Journal of molecular biology.

[10]  K Dane Wittrup,et al.  Biophysical properties of the clinical-stage antibody landscape , 2017, Proceedings of the National Academy of Sciences.

[11]  Michael J. Gramer,et al.  Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange , 2013, Proceedings of the National Academy of Sciences.

[12]  D. Röthlisberger,et al.  Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. , 2005, Journal of molecular biology.

[13]  A. Nesbitt,et al.  The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  Yvonne Stark,et al.  A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties , 2013, mAbs.

[15]  A. Nisonoff,et al.  Recombination of a mixture of univalent antibody fragments of different specificity. , 1961, Archives of biochemistry and biophysics.

[16]  S. Urlinger,et al.  In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology. , 2009, Immunotherapy.

[17]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[18]  David G Myszka,et al.  Screening antibody-antigen interactions in parallel using Biacore A100. , 2006, Analytical biochemistry.

[19]  P. Kufer,et al.  Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab , 2009, Leukemia & lymphoma.

[20]  S. Sidhu,et al.  Synthetic antibodies: concepts, potential and practical considerations. , 2012, Methods.

[21]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[22]  P. Parren,et al.  Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models , 2017, Scientific Reports.

[23]  K Dane Wittrup,et al.  Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. , 2013, Protein engineering, design & selection : PEDS.

[24]  G. Raghunathan,et al.  Antigen‐binding site anatomy and somatic mutations in antibodies that recognize different types of antigens , 2012, Journal of molecular recognition : JMR.

[25]  M. Cragg,et al.  Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies , 2015, Cancer cell.

[26]  K. Walker,et al.  Automated high-throughput protein purification using an ÄKTApurifier and a CETAC autosampler. , 2014, Journal of chromatography. A.

[27]  Andreas Plückthun,et al.  Biophysical properties of human antibody variable domains. , 2003, Journal of molecular biology.

[28]  W. Luk,et al.  Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.

[29]  G. Mufti,et al.  Role of 4-1BB:4-1BB ligand in cancer immunotherapy , 2004, Cancer Gene Therapy.

[30]  George Georgiou,et al.  In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire , 2014, Nature Medicine.

[31]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[32]  Jan Beck,et al.  Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display , 2017, Protein engineering, design & selection : PEDS.

[33]  R. Karlsson,et al.  Detection of antigen—antibody interactions by surface plasmon resonance. Application to Epitope Mapping , 1990, Journal of molecular recognition : JMR.

[34]  S. Sidhu,et al.  Bivalent antibody phage display mimics natural immunoglobulin. , 2004, Journal of immunological methods.

[35]  Camellia W. Adams,et al.  An efficient route to human bispecific IgG , 1998, Nature Biotechnology.

[36]  Sampath R. Kumar,et al.  Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients , 2017, mAbs.

[37]  A. Plückthun,et al.  Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. , 2013, Structure.

[38]  Adam R Miles,et al.  Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms , 2015, mAbs.

[39]  Yves Poitevin,et al.  Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG , 2015, Nature Communications.

[40]  L. Presta,et al.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.

[41]  Frederic A. Fellouse,et al.  Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. , 2004, Journal of molecular biology.

[42]  Ulrich Brinkmann,et al.  The making of bispecific antibodies , 2017, mAbs.

[43]  Diego Ellerman,et al.  Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.

[44]  Thomas D. Wu,et al.  Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing , 2017, Cancer cell.

[45]  S. Sidhu,et al.  Phage display for selection of novel binding peptides. , 2000, Methods in enzymology.

[46]  Jihong Wang,et al.  Improving target cell specificity using a novel monovalent bispecific IgG design , 2015, mAbs.

[47]  Rutilio H. Clark,et al.  A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism* , 2015, The Journal of Biological Chemistry.

[48]  I. Tomlinson,et al.  Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. , 1994, The EMBO journal.

[49]  K. Garcia,et al.  Durable antitumor responses to CD47 blockade require adaptive immune stimulation , 2016, Proceedings of the National Academy of Sciences.

[50]  Lawren C. Wu,et al.  Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling* , 2010, The Journal of Biological Chemistry.

[51]  M. Graf,et al.  Multiparameter RNA and Codon Optimization: A Standardized Tool to Assess and Enhance Autologous Mammalian Gene Expression , 2011, PloS one.

[52]  S. Bergqvist,et al.  Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity , 2012, Cancer Immunology, Immunotherapy.

[53]  T. Clackson,et al.  Making antibody fragments using phage display libraries , 1991, Nature.

[54]  Jan Berka,et al.  Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire , 2009, Proceedings of the National Academy of Sciences.

[55]  P. Parren,et al.  Controlled Fab-arm exchange for the generation of stable bispecific IgG1 , 2014, Nature Protocols.

[56]  P. Carter,et al.  Alternative molecular formats and therapeutic applications for bispecific antibodies. , 2015, Molecular immunology.

[57]  Thomas Waldmann,et al.  A novel solid phase technology for high-throughput gene synthesis. , 2008, BioTechniques.

[58]  E. Schmidt,et al.  Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors , 2017, Clinical Cancer Research.

[59]  D R Burton,et al.  Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Andrew D. Tustian,et al.  A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys , 2015, Scientific Reports.

[61]  Jan Kubicek,et al.  Gene optimization mechanisms: A multi-gene study reveals a high success rate of full-length human proteins expressed in Escherichia coli , 2010, Protein science : a publication of the Protein Society.

[62]  I. Melero,et al.  Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy , 2017, Clinical Cancer Research.

[63]  Pavel Strop,et al.  Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. , 2012, Journal of molecular biology.

[64]  J Witz,et al.  Thermodynamic analysis of antigen-antibody binding using biosensor measurements at different temperatures. , 1997, Analytical biochemistry.